Private Capital Ignites Europe’s Healthcare Sterilization Shift

Evolem’s Apperton deal points to consolidation in a once-fragmented corner of healthcare

6 Jan 2026

On October 6th 2025 Evolem, a French investment group, agreed to buy a majority stake in Apperton, a provider of hospital sterilisation services. The deal was modest in size. Its meaning was not. It reflects a broader shift in how Europe’s health systems treat a task that is dull, vital and increasingly hard to manage.

Sterilising surgical instruments was once handled in-house or by small local firms. That model is under strain. Rules on hygiene and traceability keep tightening. Staff are scarce. Equipment is costly to maintain and upgrade. Hospitals, under pressure to do more with less, are rethinking whether they should run such operations themselves.

Outsourcing has become the practical answer. Specialist firms can spread fixed costs, invest in compliance and promise reliability. For hospital managers, that frees time and money for patient care. Demand has risen as surgical volumes recover and grow.

Apperton operates centres mainly in France and Spain, cleaning and preparing reusable instruments for hospitals. Evolem’s bet is that this business can be scaled. The aim is not quick savings but steady growth: expanding capacity, improving logistics and widening geographic reach. With size comes an easier path to meeting regulation and serving large hospital groups that want consistent service across multiple sites.

This logic is driving consolidation. Big international providers already enjoy standardised processes and deep pockets. Regional firms have struggled to keep up. Private capital offers a bridge. With new funding, Apperton can invest in quality and partnerships, and present itself as a credible alternative to global giants.

The risks are familiar. Integrating sites takes time. Hospitals worry about relying on fewer suppliers, especially for a function tied directly to patient safety. Any failure would be costly in more ways than one.

Even so, the direction is clear. Sterilisation is no longer a back-office chore. It is infrastructure. As money flows in and standards rise, Europe’s sterilisation market is becoming a strategic field where scale, safety and long-term investment matter more than ever.